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The Immunoglobulin Class Switch: Minireview
Beyond ªAccessibilityº
Clifford M. Snapper,* Kenneth B. Marcu,² species encoded by different CH genes in the germline
(Stavnezer-Nordgren and Sirlin, 1986; Yancopoulos etand Piotr Zelazowski*
*Department of Pathology al., 1986). Germline CH RNAs are spliced products of
distinct I exons, located 59 to every S region, and theThe Uniformed Services University
of the Health Sciences immediate 39 CH gene (Figure 1). Transcription initiates
within a promoter 59 to the I exon, proceeds throughBethesda, Maryland 20814
²Department of Biochemistry and Cell Biology the S region, and terminates at the 39 end of the CH gene.
Splicing out of the S region creates the final germline CHState University of New York at Stony Brook
Stony Brook, New York 11794 RNA (i.e., 59 IHCH 39) (Lutzker and Alt, 1988; Gaff and
Gerondakis, 1990; Gerondakis, 1990; Lebman et al.,
1990; Radcliffe et al., 1990; Rothman et al., 1990). Multi-
ple chimeric germline CH transcripts (ImCe, IeCm, ImCg4,Induction of germline constant heavy (CH) gene tran-
IgCm, IgCe, IeCg, and Ig4Ca1) have also been demon-scription by cytokines, B cell activators, or both is a key
strated in IgD1 human B cells stimulated by IL-4 alone,event for targeting the CH gene for subsequent switch
in the apparent absence of either genomic switch re-rearrangement. An increase in transcriptional activity
combinations or their circular by-products (Fujieda etmay confer to the CH locus a state of enhanced accessi-
al., 1996). The authors interpret their findings as evi-bility for the binding of additional factors important for
dence for trans-splicing of unrearranged germline im-mediating the switching event. This regulatory paradigm
munoglobulin RNA transcripts. Additionally, spliced hy-is known as the ªaccessibilityº model of immunoglobulin
brid ImCg transcripts can form subsequent to switchclass switching. Here we discuss recent studies demon-
recombination through processing of a single RNA tran-strating the ability of interleukin-4 (IL-4), IL-5, IL-10, in-
script containing the juxtaposed Im and Cg regions andterferon-g (IFNg), membrane immunoglobulin±mediated
accumulate along with the respectively mature Cg RNAactivation, and the transcription factor, p50/NF-kB to
(Li et al., 1994). These data are consistent with the modelmediate distinct and profound changes in immunoglob-
that simultaneous germline expression of both 59 andulin class switching in the absence of corresponding
39 CH genes (Cm and Cg) is involved in targeting theiralterations in germline CH RNA expression. These stud-
subsequent switch recombination. Germline CH RNAsies suggest novel modes of regulation of the immuno-
lack VDJ-encoded sequence and hence cannot, byglobulin class switch that may involve levels of ac-
themselves, direct synthesis of intact immunoglobulincessibility distinct from transcriptional activation or
molecules. One group has shown that a germline CHalterations in the recombination machinery itself (or
transcript has the potential to encode a truncated Cmboth).
protein in vitro (Bachl et al., 1996). However, the potentialThe immunoglobulin class switch is a process that is
existence of germline CH RNA±encoded, truncated CHcritical for the generation of functional diversity of a
proteins in vivo remains controversial, as most I exonshumoral immune response (for review see Coffman et
contain translation stop codons in each reading frameal., 1993; Harriman et al., 1993; Snapper and Finkelman,
(Lennon and Perry, 1985). Upon switch rearrangement,1993; Lorenz and Radbruch, 1996; Stavnezer, 1996). At
the I and S regions are deleted and the relevant CH genethe cellular level, switching is manifested by the transi-
is brought into proximity with the VDJ gene (Figure 1). Intion from B cells expressing membrane immunoglobulin
this position it encodes a productive VDJ-CH RNA forM (mIgM), IgD, or both to those expressing IgE, IgA, or
synthesis of an intact immunoglobulin molecule ex-one of four IgG subclasses. Immunoglobulin classes
pressing the same antigen specificity but a new immu-are encoded by CH genes aligned in tandem, 39 to a
noglobulin class.rearranged VDJ gene that encodes for antigen specific-
ity. 59 to each CH gene, except CHd, are blocks of tan-
demly repetitious DNA sequences, termed switch (S) The ªAccessibilityº Model of Immunoglobulin
regions. At the molecular level, the predominant mode Class Switching
of immunoglobulin class switching comprises a recom- The immunoglobulin class switch is influenced in both
bination event that includes looping out and deletion of a positive and negative manner by a number of cytokines
all CH genes 59 to the CH gene that is to be expressed and B cell activators. The mechanism for this appears
(Iwasato et al., 1990; Matsuoka et al., 1990; von- to lie in part in the ability of cytokines and activators to
Schwedler et al., 1990) (Figure 1). In a B cell that is initially regulate transcription selectively, which initiates up-
mIgM1, this recombination event occurs between Sm stream of each of the I exons. This effect is manifested
and the S region of the downstream CH gene. Sequential by changes in the steady-state levels of the different
switching may also occur through the deletion mecha- germline CH RNA after activation. The selectivity of this
nism (Mills et al., 1992, 1995; Siebenkotten et al., 1992; process lies in the presence of unique sequences 59 to
Mandler et al., 1993a). each I exon for binding of a series of regulatory proteins
whose expression within the B cell may be influenced
by the activation conditions. However, the function ofGermline CH RNA
Prior to switch rearrangement, populations of activated the I exon itself is unknown. Based upon precedents in
other cellular systems, it has been proposed that theB cells typically express one or more characteristic RNA
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Figure 1. Schematic of the Immunoglobulin Class Switch (e.g., IgM to IgG1)
events that initiate germline CH transcription also confer 1990; Daniels and Lieber, 1995a, 1995b). Thus, a cellular
switch-recombinase activity appears to operate on ap-a level of accessibility to the CH locus for the binding of
additional regulatory elements that participate in switch propriate switch sequences even when they are present
outside of their natural chromosomal contexts. The Srecombination (i.e., the accessibility model of immuno-
globulin class switching; Stavnezer-Nordgren and Sirlin, sequence±specific-recombinase activityacting onchro-
mosomally integrated switch substrates also appears1986; Yancopoulos et al., 1986).
Analyses of switch-recombinase substrates, either to be B-cell specific (Ott et al., 1987; Ott and Marcu,
1989; Leung and Maizels, 1992, 1994; Ballantyne et al.,chromosomally integrated or in an episomal state, have
engendered further support for the accessibility model 1995, 1997; Daniels and Lieber, 1995a). One study dem-
onstrated that Sg and Sa substrate sequences couldby demonstrating a requirement for substrates to be
transcriptionally active in order to undergo switch re- recombine with Sm in the same pre-B cell line, implying
that a common recombinase may exist for all S se-arrangement (Ott et al., 1987; Ott and Marcu, 1989;
Leung and Maizels, 1992, 1994; Ballantyne et al., 1995; quences (Lepse et al., 1994). In contrast, replicating ex-
trachromosomal switch substrates (unlike their naturalDaniels and Lieber, 1995a). Further, this transcriptional
requirement is DNA-strand specific (Reaban and Griffin, genomic counterparts or integrated, proviral substrates;
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Ott et al., 1987; Ott and Marcu, 1989; Ballantyne et al., Another group has independently hypothesized that
such S sequence±specific RNA:DNA hybrids could indi-1995, 1997) undergo significant recombination in inap-
propriate cell types and can also produce non-S se- rectly enhance the overall recombinagenic activity of
S regions by specifically facilitating the formation ofquence recombination products (Leung and Maizels,
1992, 1994; Daniels and Lieber, 1995a), implying that nuclease-sensitive, short stem loop structures among
the self-complementary S region tandem repeats (Baarconstraints of substrate specificity are more relaxed on
such replicating episomal, recombination targets. Re- et al., 1996).
Over and above control of germline CH RNA expres-cent work with single copy, chromosomally integrated
retroviral substrates indicates that recombinase activity sion by a promoter 59 to the I exon, IgH locus transcrip-
tional control in more general terms is orchestratedis not only B-cell specific, but B cell±stage specific (re-
stricted to cell lines representing late stage pre-B and through the actions of an intronic enhancer (Em), located
between JH and CHm, and a developmentally regulatedmature B cells; Ballantyne et al., 1997). Furthermore, the
recombinase activity was found to act in a stochastic enhancer complex located 39 of Ca (39E) and consisting
of four enhancers: a39E, 39E-HS1,2, 39E-HS3, and 39E-fashion upon constitutively accessible (i.e., transcribed)
S region targets, in that switch recombinations were HS4 (Dariavach et al., 1991; Lieberson et al., 1991; Mat-
thias and Baltimore, 1993; Madisen and Groudine, 1994;found to be chance events likely occurring with similar
probability from one cell generation to the next (Ballan- Michaelson et al., 1995). Em is implicated, through its
early transcriptional activation of DJ-CHm sequences, intyne et al., 1997). Whether the switch-recombinase ac-
tivity itself is subject to regulation by various B cell making Sm accessible for subsequent recombination
with downstream S regions (Gu et al., 1993). One studystimuli remains an open question.
Two recent reports employing homologous gene tar- employing episomal S sequence substrates observed
that Em was even capable of stimulating switch recombi-geting in mice have now shown that I regions strongly
target class switching to specific S regions beyond their nation above its effects on transcriptional activity (Leung
and Maizels, 1994). The evidence for a role of the 39Eability simply to induce transcription (Bottaro et al.,
1994; Lorenz et al., 1995). In one of these studies it was region in germline CH transcription comes from homolo-
gous gene targeting in mice. Here, replacement of 39E-proposed that the spliced IHCH RNA may also be required
(Lorenz et al., 1995). Bottaro et al. (1994) have shown HS1,2 by a heterologous neomycin gene expression
cassette strongly repressed most germline CH RNAsthat when the natural lipopolysaccharide (LPS)/IL-4-
inducible Ie promoter and exon is replaced by an LPS- (Cogne et al., 1994). As anticipated from the accessibility
model, this was associated with a marked reduction ininducible Em enhancer/VH promoter, switching to IgE is
inhibited, in cis, by 10- to 100-fold in spite of substantial switch rearrangements of the corresponding CH genes.
However, the foreign neo expression cassette may havetranscription through the Se region of the targeted allele.
Therefore, optimal switching requires an intact I region contributed to the latter effects by disturbing, perhaps
through enhancer competition, the function of the otheror I region promoter in cis (or both) beyond their contri-
butions to S region transcription. Lorenz, Jung, and Rad- enhancers of the 39E region or other yet to be defined
regulatory elements. A study demonstrating that the twobruch went on to report that the Ig1 exon sequences
encompassing the splice donor signal were necessary most distal enhancers of the 39E may impart additional
properties to the more proximal enhancers is consistentand sufficient for normal levels of switching to IgG1,
implying that the spliced germline transcript or the with the notion that the 39E acts as a locus control region
(Madisen and Groudine, 1994). The 39E region may se-spliceosome complex was in some way required for
subsequent switch recombination. However, in this lat- lectively regulate transcription of germline CH RNAs, but
the nature of the cross-talk between individual I exon±ter study the mutant g1 locus that retained the I exon
splice donor possessed much higher transcriptional ac- associated promoters and specific 39E enhancers re-
mains to be delineated.tivity than the switching-defective, mutant g1 locus
which lacked the same splice donor signal. Therefore, An extensive literature lends strong support for the
accessibility model of immunoglobulin class switching.a more direct role of the processed germline transcript
or its splicing intermediate in subsequentswitch-recom- This is evidenced by numerous observations that
switching to a particular immunoglobulin class is alwaysbination remains controversial.
It has been suggested that transcription of S se- preceded by the appearance of germline CH RNA corre-
sponding to that class (Coffman et al., 1993; Harrimanquences prior to their recombination may produce an
RNA:DNA triplex switch recombination substrate. Re- et al., 1993; Snapper and Finkelman, 1993; Lorenz and
Radbruch, 1996; Stavnezer, 1996). Further, several stud-aban and Griffin first demonstrated that the supercoiled
state of Sa polypurine repeats is lost upon their tran- ies have demonstrated a direct correlation between cy-
tokine-mediated induction of germline CH RNA and en-scription, but that the configuration of these repeats
remains stable by virtue of DNA strand±specific RNA: hanced transcriptional rate at the relevant CH locus
(Rothman et al., 1991; Shockett and Stavnezer, 1991;DNA hybrid formation. It was suggested that such stabi-
lized, triplex strands of RNA:DNA conformers would ex- Lorenz et al., 1995), although a single report challenged
this notion (Lebman et al., 1994). Although germline CHist just prior to switch recombination (Reaban and Grif-
fin, 1990). In vitro transcription of Sg sequences has RNA can be induced in a resting B cell, such cells will
not undergo switch rearrangement unless they have alsoalso recently been shown to produce strand-specific
RNA:DNA hybrid structures, providing additional sup- entered the cell cycle (Severinson et al., 1982; Kenter
and Watson, 1987; Lundgren et al., 1995). Several re-port for the idea of an RNA:DNA intermediate culminat-
ing in switch recombination (Daniels and Lieber, 1995b). ports have suggested a direct role for DNA synthesis as
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Table 1. Changes in Immunoglobulin Class Switching Independent of Alteration in Germline CH RNA Expression
Immunoglobulin
``Switch Factor'' Isotype Activation Conditions Reference
IL-4 ↑ IgA CH12F3 B lymphoma 1/2 Nakamura et al., 1996
CD40 ligand and/or TGFb
IL-5 ↑ IgG1 Anti-Ig-dex 1 IL-4 Mandler et al., 1993
↑ IgG1 1 IgE Sepharose±anti-Ig 1 LPS Purkerson and Isakson, 1992
IL-10 ↑ IgG3 LPS Shparago et al., 1996
↓ IgA LPS 1 IL-4 1 IL-5 1 anti-Ig-dex 1 TGFb Shparago et al., 1996
IFNg ↓ IgG3 LPS Severinson et al., 1990
Zelazowski et al., 1995
Anti-Ig-dex ↓ IgG1 LPS 1 IL-4 Zelazowski et al., 1995
Pharmacologic Agent
DSCG ↓ IgE (human) Anti-CD40 1 IL-4 Loh et al., 1994
Transcription Factor
p50/NF-kB knockout ↓ IgA LPS 1 IL-4 1 IL-5 1 anti-Ig-dex 1 TGFb Snapper et al., 1996
Unless otherwise indicated, these studies utilized normal murine B cells in vitro. DSCG, disodium cromoglycate.
an element or component of the switch rearrangement al., 1988; Rothman et al., 1988). A role for IL-4 in switch-
ing to IgA was recently assessed using a B cell lym-process (Dunnick et al., 1989; Dunnick and Stavnezer,
phoma model. CH12F3, a subclone of the CH12.LX B1990) and even germline CH RNA expression (Lundgren
cell lymphoma which constitutively expresses germlineet al., 1995), but the molecular mechanisms remain to
CHa RNA, is induced to switch at a high frequencybe elucidated.
(z50%) in response to the combination of CD40 ligand,
IL-4, and transforming growth factor b (TGFb) (Naka-
Switch Rearrangement May Be Regulated mura et al., 1996). IL-4 alone enhances switching to IgA
Independently from Alterations in Germline (up to12%) inCH12F3 cells without altering their steady-
CH RNA Expression: An Expanded View of state levels of germline CHa RNA. In contrast, CD40
Immunoglobulin Class Switch Regulation ligand or TGFb alone stimulated an increase in the levels
Although DNA synthesis and germline CH gene transcrip- of germline CHa RNA, and this was associated in each
tion appear to be necessary for switch rearrangement case with an increase in switching to IgA (up to 12%).
to occur, a large body of evidence, utilizing normal and However, an additive effect on switching to IgA by CD40
transformed murine B cells, now strongly suggests that ligand plus TGFb (22%) is observed in the absence of
these two processes are not sufficient. Indeed, a series an associated increase in germline CHa RNA levels
of regulated events in cycling B cells has been observed above that seen with either agent acting alone. This
that leads to striking changes in switch rearrangement latter finding suggested the possibility that, in addition
without corresponding changes in germline CH RNA ex- to IL-4, CD40 ligand, TGFb, or both may enhance Sm±Sa
pression. These observations, discussed in detailbelow, rearrangement events independently of alterations in
imply that in addition to germline CH transcription, addi- germline CHa transcription. IL-4 also augments switch-
tional events under the control of a number of cytokines, ing to IgA in normal murine B cells activated in vitro with
B cell activators, and transcription factors (summarized LPS or CD40 ligand plus IL-5, anti-Ig-dex, and TGFb
in Table 1) or other targeting factors may also be central (McIntyre et al., 1995).
to controlling the immunoglobulin class switch. The
IL-5identification of these regulated components represents
Dextran-conjugated anti-immunoglobulin antibodiesa key challenge for investigators in the field.
(anti-Ig-dex) stimulate resting B cells to synthesize DNAIn most of the studies discussed below, three method-
(Brunswick et al., 1988). In consideration of the accessi-ologies were utilized to assess immunoglobulin class
bility model it was predicted that induction of germlineswitching: flow cytometric analysis of the percentage
CHg1 transcription in response to the IL-4 IgG1 switchof B cells expressing various mIg isotypes consequent
factor would be sufficient to trigger Sm±Sg1 rearrange-to in vitro activation; digestion circularization±poly-
ment in B cells induced to enter the cell cycle and syn-merase chain reaction (DC±PCR) for quantitating spe-
thesize DNA upon anti-Ig-dex activation. However,cific switch rearrangement events at the DNA level (Chu
despite IL-4 induction of germline CHg1 RNA in anti-Ig-et al., 1992); and semi-quantitative reverse transcrip-
dex-activated B cells, no corresponding increase in thetion±PCR for comparative assessment of germline CH
percentage of mIgG11 cells or Sm±Sg1 rearrangementRNA expression.
events was observed (Mandler et al., 1993b). Surpris-
ingly, further addition of IL-5, a cytokine initially de-
IL-4 scribed for its ability to promote B cell differentiation to
IL-4 is a switch factor for the IgG1 (Isakson et al., 1982; immunoglobulin secretion, strongly induced the appear-
Severinson et al., 1982) and IgE isotypes (Coffman and ance of mIgG11 cells and Sm±Sg1 rearrangements. IL-5
Carty, 1986), and this property is associated with IL-4 mediated this effect without altering the levels of germ-
line CHg1 RNA and with only a modest enhancement ininduction of germline CHg1 and CHe RNA (Stavnezer et
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DNA synthesis. In the absence of IL-4-mediated tar- in LPS-activated cells could either result from a direct
inhibitory effect of IFNg on Sm±Sg3 recombination orgeting of the CHg1 gene, IL-5 by itself fails to induce
switching to IgG1 in anti-Ig-dex-activated cells. This perhaps reflect sequential switching from IgM to IgG3
to IgG2a.suggested that IL-5 provides a critical signal that allows
switching to IgG1 to occur in a cycling B cell with a
transcriptionally active germline CHg1 gene. Since IL-4 Membrane Immunoglobulin Cross-Linking
is required for germline CHg1 RNA expression, another Multivalent mIg cross-linking, using anti-Ig-dex, by itself
independent role(s) for this cytokine in promoting Sm± induces a modest increase in the levels of germline CH
Sg1 rearrangement cannot be assessed in this system. RNA specific for IgG3, IgG1, and IgG2b in resting B cells
IL-5 has also been found to promote switching to IgE, as (Zelazowski et al., 1995). This is associated with the
well as IgG1, without altering the corresponding levels induction of small amounts of secreted IgG3 and IgG1,
of germline CHe and CHg1 RNA in anti-immunoglobulin- although not IgG2b, by anti-Ig-dex-activated B cells in
activated normal murine B lymphoblasts cultured in the the presence of IL-5. The additional capacity of anti-Ig-
presence of LPS (Purkerson and Isakson, 1992). dex to inhibit switching to IgE in B cells activated with
LPS plus IL-4 is associated with a marked reduction
in the levels of germline CHe RNA, consistent with theIL-10
accessibility model (PecË anha et al., 1993; ZelazowskiIL-10 strongly inhibits the generation of mIgA1 cells and
et al., 1995). However, the 50% inhibition of LPS plusSm±Sa rearrangements in normal murine B cells in re-
IL-4±mediated switching to IgG1 by anti-Ig-dex is asso-sponse to combined activation with LPS, IL-4, IL-5, anti-
ciated with a greater than 7-fold increase in the levelsIg-dex, and TGFb (Shparago et al., 1996). This effect of
of germline CHg1 RNA (Zelazowski et al., 1995). Hence,IL-10 occurs in the absence of significant alterations in
mIg cross-linking can selectively regulate immunoglob-germline CHa RNA expression or substantial changes in
ulin class switching in a manner that appears to beDNA synthesis. In contrast, IL-10 augments the genera-
both dependent and independent of changes in CH genetion of mIgG31 cells and Sm±Sg3 rearrangements in re-
transcription.sponse to activation with LPS alone (Shparago et al.,
1996). The inductive effect of IL-10 on LPS-mediated
switching to IgG3 is also not associated with significant p50/NF-kB
alterations in germline CHg3 RNA, although IL-10 inhibits The IgH locus contains multiple binding sites for the NF-
LPS-mediated DNA synthesis. Thus, IL-10 selectively kB/Rel family of transcription factors. In particular, p50-
regulates immunoglobulin class switching in murine B binding sites have been identified in Ig3 (Gerondakis et
cells in a manner that appears to be independent of al., 1991), Ig1 (Lin and Stavnezer, 1996), and Ie (Delphin
changes in germline CH transcription. IL-10 also induces and Stavnezer, 1995), as well as in 39E-HS1,2 and 39E-
switching to IgG1 and IgG3 in CD40-activated naive HS4 (Michaelson et al., 1996). In addition, p50-binding
human B cells (Briere et al., 1994; Malisan et al., 1996), sites have been identified in Sg3, Sg1, and Sg2b in prox-
but the mechanism underlying this selectivity has not imity to sites of recombination within the switch region
yet been reported. However, activation of human B cells (Wuerffel et al., 1990, 1992; Kenter et al., 1993). In this
with anti-CD40 antibody alone induces multiplegermline regard, B cells from mice made genetically deficient
CH RNAs, including IgG1 and IgG3 (Jumper et al., 1994). in p50/NF-kB (p502/2) demonstrate selective defects in
This suggests that, as in the mouse, IL-10 may promote germline CH RNA expression and immunoglobulin class
switching in human B cells in a manner that is indepen- switching in vitro relative to wild-type controls (Snapper
dent of alterations in germline CH RNA expression. Alter- et al., 1996). In p502/2 B cells, defective expression of
natively, IL-10 may up-regulate the levels of germline CHg3 and CHe RNA correlate with a corresponding inabil-
CHg1 and CHg3 RNA above some threshold that is critical ity to switch to IgG3 and IgE, as anticipated by the
for switching to occur. accessibility model. Likewise, normal expression of
germline CHg1 RNA by p502/2 B cells is associated with
near normal levels of switching to IgG1. However, p502/2IFNg
B cells demonstrate a substantial defect in switching toIFNg promotes switching to IgG2a in LPS- and anti-Ig-
IgA despite expressing normal levels of germline CHadex-activated B cells (Snapper and Paul, 1987; Snapper
RNA. These datasuggest a role for p50/NF-kB in regulat-et al., 1992). These effects of IFNg are associated with
ing immunoglobulin class switching that is both depen-a corresponding induction of germline CHg2a RNA (Sev-
dent and independent of alterations in germline CH tran-erinson et al., 1990; Collins and Dunnick, 1993). IFNg
scription.also induces switching to IgG3 in anti-Ig-dex-activated
B cells and, likewise, this induction correlates with an
increase in the levels of germline CHg3 RNA (Snapper A Role for Ku in Switch Recombination?
The nuclear components responsible for effecting theet al., 1992). In contrast, IFNg inhibits LPS-mediated
switching to IgG3 and IgG2b (Snapper and Paul, 1987). switch recombination event are unknown. Potential can-
didates may include a variety of regulatory proteins thatWhereas inhibition of switching to IgG2b is associated
with a reduction in the levels of germline CHg2b RNA, participate in DNA replication, repair, and/or recombina-
tion and whose expression could in theory be regulated.as anticipated by the accessibility model, IFNg suppres-
sion of LPS-induced switching to IgG3 is not associated In this regard, a recent report compared the capacity
of Bcell precursors from RAG-2-deficient and SCID micewith a corresponding reduction in the levels of germline
CHg3 RNA (Severinson et al., 1990; Zelazowski et al., to undergo Sm±Se recombination in response to anti-
CD40 monoclonal antibody plus IL-4 (Rolink et al., 1996).1995). The ability of IFNg to suppress switching to IgG3
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